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ABSTRACT
Background & Aims: In hepatocellular carcinoma (HCC), CD8+ T-cell responses 
targeting tumor-associated antigens (TAA) are considered to be beneficial. However, 
the molecular profile of TAA-specific CD8+ T cells in HCC is not well defined due to 
their low frequency.
Results: In this study, we demonstrate that TAA-specific CD8+ T-cell responses 
are not efficiently induced in the peripheral blood of HCC patients as supported by the 
following observations: First, in HCC patients, frequencies of TAA-specific CD8+ T cells 
were not increased compared to healthy donors (HD) or patients with liver cirrhosis. 
Second, a remarkable proportion of TAA-specific CD8+ T cells were naïve despite 
the presence of antigen within the tumor tissue. Third, antigen-experienced TAA-
specific CD8+ T cells lack the characteristic transcriptional regulation of exhausted 
CD8+ T cells, namely EomeshiTbetdim, and express inhibitory receptors only on a minor 
proportion of cells. This suggests restricted antigen recognition and further supports 
the hypothesis of inefficient induction and activation.
Methods: By applying peptide/MHCI tetramer-based enrichment, a method of high 
sensitivity, we now could define the heterogeneity of circulating TAA-specific CD8+ T 
cells targeting glypican-3, NY-ESO-1, MAGE-A1 and MAGE-A3. We focused on therapy-
naïve HCC patients of which the majority underwent transarterial chemoembolization 
(TACE).
Conclusion: Our analysis reveals that circulating TAA-specific CD8+ T cells 
targeting 4 different immunodominant epitopes are not properly induced in therapy-
naïve HCC patients thereby unravelling new and unexpected insights into TAA-
specific CD8+ T-cell biology in HCC. This clearly highlights severe limitations of these 
potentially anti-tumoral T cells that may hamper their biological and clinical relevance 
in HCC.
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INTRODUCTION
Hepatocellular carcinoma (HCC) is the most 
common type of primary liver cancer in adults and 
occurs predominantly in patients with underlying chronic 
liver disease and cirrhosis. It has a poor prognosis and 
therapeutic options are limited [1]. There is growing 
interest to treat HCC with immunotherapeutic approaches 
as several studies have indicated a role of innate and 
adaptive immunity in HCC progression and control. For 
example, lymphocytic infiltrates, in particular tumor-
infiltrating T cells that occur during natural disease 
progression or that are induced by different therapies, have 
been shown to be associated with improved relapse-free 
survival [2–4]. In addition, the PD1 inhibitor nivolumab 
has recently shown durable objective responses in patients 
with advanced HCC further indicating a role of adaptive 
immunity, especially of T cells in HCC progression versus 
control [5].
The tumor antigens recognized by T cells have not 
been well characterized and may consist of immunogenic 
neoantigens that have not been identified yet in HCC. 
However, several TAAs have been shown to be expressed 
in human HCC [6–13]. TAAs comprise a range of self-
derived proteins, such as a-fetoprotein (AFP), glypican-3 
(GPC-3), New York esophageal squamous cell carcinoma 
(NY-ESO-1) or the melanoma-associated gene-A 
(MAGE-A) that can become immunogenic in HCC either 
by mutation or aberrant expression. TAAs show different 
expression rates with e. g. MAGE-A being expressed in 
up to 80% and NY-ESO-1 being expressed in less than 
50% of HCC patients [14–16]. Importantly, there is 
growing evidence that these TAAs can be recognized 
by specific CD8+ T-cell responses. Indeed, CD8+ T-cell 
responses targeting different TAAs have been reported in 
several studies. Collectively, the results of these studies 
have given important insights into HCC immunobiology 
that can be summarized as follows: First, the overall 
frequency of TAA-specific CD8+ T-cell responses is 
very low and most T-cell responses were only detectable 
after antigen-specific [6, 17] or -unspecific [7, 14] 
expansion. Thus, it has been postulated that the overall 
amount of TAA-specific CD8+ T cells might be too low 
to eliminate HCC. Second, however TAA-specific CD8+ 
T-cell responses have been shown to be associated with 
improved survival indicating at least a partial biological 
relevant activity despite their overall low frequency. Third, 
TAA-specific CD8+ T cells are impaired in their effector 
functions [18], e. g. showing a reduced TAA-specific 
cytokine production or killing capacity. The mechanisms 
responsible for this TAA-specific CD8+ T-cell dysfunction 
are not well understood but several factors e. g. the 
expression of inhibitory receptors such as PD-1 [18–20], 
the immunosuppressive tumor microenvironment [21, 22], 
the lack of sufficient CD4+ T-cell help [18, 19] or the 
action of suppressive cytokines [21], regulatory T cells 
or myeloid derived suppressor cells [17, 19, 21, 22] have 
been suggested to contribute.
Despite all these important insights into TAA-
specific CD8+ T-cell immunity, their low frequency and 
thus the requirement for in vitro expansion for proper 
T-cell analysis has hampered the analysis of the ex vivo 
molecular properties of TAA-specific CD8+ T cells 
in HCC. Indeed, only a few studies have analyzed the 
TAA-specific CD8+ T-cell responses ex vivo by pMHCI-
tetramers and were also limited by the small amount of 
detectable cells [20, 23]. Thus, little is known about the 
ex vivo frequency of TAA-specific CD8+ T cells, their 
differentiation status, e. g. expression of exhaustion 
markers, their association with antigen expression 
and response to conventional HCC therapy. Here, by 
performing pMHCI-tetramer-based enrichment that allows 
the detection and characterization of rare antigen-specific 
CD8+ T-cell populations as well as an estimation of their 
frequency, we set out to address these important questions. 
Noteworthy, by using this sensitive approach, we were 
previously able to define key characteristics of HCV-
specific CD8+ T cells [24, 25]. In this study, we show 
that circulating TAA-specific CD8+ T cells are indeed 
present at very low frequencies even after applying high-
sensitivity pMHCI-tetramer-based enrichment probably 
due to inefficient TAA-specific CD8+ T-cell induction in 
HCC patients. In line with this, we observed circulating 
TAA-specific CD8+ T cells with a naïve phenotype and 
the absence of exhausted TAA-specific CD8+ T cells, both 
indicative of inefficient activation and restricted antigen 
recognition. Thus, this comprehensive analysis gives 
important novel insights into circulating TAA-specific 
CD8+ T-cell responses in HCC and clearly highlights 
severe limitations of these potentially anti-tumoral T cells 
that may hamper their biological and clinical relevance.
RESULTS
pMHCI-tetramer enrichment reveals 
comparable detection rate and frequency of 
circulating TAA-specific CD8+ T cells in healthy 
donors, patients with liver cirrhosis and HCC 
patients
In a first set of experiments, we performed pMHCI-
tetramer-based enrichment to screen a cohort of 47 
therapy-naïve HCC patients (Supplementary Table 1) for 
the presence of circulating TAA-specific CD8+ T cells 
targeting the HLA-A*02-restricted epitopes NY-ESO-1157, 
MAGE-A3271, Glypican-3521 and AFP47, and the HLA-
A*03-restricted epitopes MAGE-A196, and Glypican-3519. 
This approach was used to increase the detection rate 
of circulating TAA-specific CD8+ T-cell responses that 
have been previously reported to be very low [6, 7, 14]. 
Indeed, by conventional ex vivo pMHCI-tetramer staining, 
we failed to detect any TAA-specific CD8+ T cells. By 
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using the pMHCI-tetramer-based enrichment strategy, it 
turned out that Glypican-3- and AFP-specific CD8+ T 
cells could not be reliably enriched using Glypican-3521/
HLA-A*02 and AFP47/HLA-A*02 tetramers (data not 
shown). Furthermore, only a minority of HCC patients 
displayed detectable CD8+ T-cell responses against the 
HLA-A*02-restricted NY-ESO-1157 (14%) and HLA-
A*03-restricted Glypican-3519 (8%) epitopes. However, 
15 out of 32 HCC patients (47%) showed a CD8+ T-cell 
response against the HLA-A*02-restricted MAGE-A3271 
and 7 out of 18 HCC patients (39%) a response against 
the HLA-A*03-restricted MAGE-A196 epitope (Figure 
1A). Overall, this is a rather low detection rate since by 
using the same approach we were previously able to detect 
HCV-specific CD8+ T-cell responses in the majority of 
chronically infected patients [24]. Thus, these results 
show that circulating TAA-specific CD8+ T-cell responses 
are rarely detectable despite applying high-sensitivity 
techniques like pMHCI-tetramer enrichment.
To determine whether circulating TAA-specific 
CD8+ T-cell responses are specific for cancer patients, in 
this case for HCC, we next compared their detection rates 
and frequencies in HCC patients with the detectability in 
healthy donors (HD; n = 28; Supplementary Table 2) and 
in patients with liver cirrhosis (n = 29; Supplementary 
Table 3). For this analysis, based on the very low detection 
rates of NY-ESO157- and Glypican-3519-specific CD8+ 
T-cell responses, we only focused on MAGE-A3271- and 
MAGE-A196-specific T cells. Importantly, as shown in 
Figure 1B, MAGE-A3271-specific CD8+ T cells showed 
a similar detection rate and frequency in all three tested 
cohorts. In the case of MAGE-A196-specific CD8+ T-cell 
responses, the detection rate was somewhat, but not 
significantly, lower in HD compared to the HCC and liver 
cirrhosis cohorts (30% versus 53% (cirrhosis), and 39% 
(HCC)), however, the frequencies of detectable CD8+ 
T-cell responses were in the same range (Figure 1C). 
Taken together, these results indicate a comparable 
presence of circulating TAA-specific CD8+ T cells in the 
different cohorts and surprisingly the absence of a specific 
expansion of TAA-specific CD8+ T cells in HCC patients.
Antigen-experienced TAA-specific CD8+ T cells 
are present in HCC with a high inter-individual 
variability
The low frequency and lack of expansion of 
circulating TAA-specific CD8+ T cells prompted us to 
address the question whether these cells were indeed 
antigen-experienced and had thus been primed and 
activated in vivo. For this analysis, pMHCI-tetramer-
enriched MAGE-A196- and MAGE-A3271-specific CD8+ 
T cells were analyzed for the expression of CCR7 and 
CD45RA. Antigen-experienced cells are defined by a 
phenotype being either CD45RA+CCR7-, CD45RA-
CCR7- or CD45RA-CCR7+ whereas naïve cells are 
defined by a CD45RA+CCR7+ phenotype. Of note, 
as shown in Figure 2A and 2B, we found substantial 
differences in the proportion and frequency of antigen-
experienced MAGE-A-specific CD8+ T cells between 
the different cohorts. As expected, in HD, circulating 
MAGE-A-specific CD8+ T cells largely displayed a naïve 
CD45RA+CCR7+ phenotype suggesting that these cells 
have not been primed in vivo (% antigen-experienced 
MAGE-A-specific CD8+ T cells in HD: Median: 7.0%; 
IQR: 23.6%). In contrast, circulating MAGE-A-specific 
CD8+ T cells obtained from HCC patients largely 
consisted of antigen-experienced cells, however, with a 
high inter-individual variability (HCC: Median: 52.9%; 
IQR: 60.8%). Indeed, some HCC patients displayed 
MAGE-A-specific CD8+ T-cell responses with an 
almost exclusive naïve phenotype, indicating that these 
circulating cells may not have been primed in vivo or may 
exhibit a naïve-like phenotype due to abortive activation.
Lower frequency of antigen-experienced TAA- 
versus virus-specific CD8+ T cells in HCC 
patients
Next, we asked whether the low frequency of 
circulating TAA-specific CD8+ T cells and their highly 
variable antigen-experienced phenotype may constitute a 
general feature of antigen-specific CD8+ T-cell responses 
present in HCC patients. To address this question, we 
analyzed MAGE-A-specific and virus-specific CD8+ 
T cells targeting Influenza, CMV and EBV in the blood 
of HCC patients. As shown in Figure 3A, virus-specific 
CD8+ T cells were present in HCC patients in at least a 
three log higher frequency compared to MAGE-A-specific 
CD8+ T cells. This holds true for both tested MAGE-A-
specific epitopes, MAGE-A196 and MAGE-A3271. The 
frequency of virus-specific CD8+ T cells, however, 
was not affected by the presence of HCC as similar 
frequencies were observed in HD (HCC: Median: 6.4*10-
3; IQR: 7.1*10-3; HD: Median: 9.2*10-3; IQR: 1.2*10-3). 
Additionally, all virus-specific CD8+ T cells displayed 
an antigen-experienced phenotype in HCC patients and 
HD (Figure 3B). Thus, these results show that the low 
frequency and heterogeneous phenotype of MAGE-A-
specific CD8+ T cells cannot be attributed to general 
tumor-specific factors that actively affect all antigen-
specific CD8+ T cells but that this is rather a TAA-specific 
feature.
Transarterial chemoembolization does not lead 
to stable induction or enhancement of circulating 
TAA-specific CD8+ T-cell responses
Previously, it was shown that ablative therapy 
leads to an activation and enhancement of TAA-specific 
CD8+ T cells [23]. Thus, we next analyzed the MAGE-
A-specific CD8+ T-cell response in 13 patients of our 
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Figure 1: Different detection rates and frequencies of circulating TAA-specific CD8+ T cells. Detection rates of circulating 
TAA-specific CD8+ T-cell responses targeting NY-ESO-1157/HLA-A*02, Glypican-3519/HLA-A*03, MAGE-A3271/HLA-A*02 and 
MAGE-A196/HLA-A*03 differ in HCC patients. Representative flow cytometry plots are displayed and pie charts depicting absence 
(grey) and presence (black) of detectable TAA-specific T-cell responses (A). Detection rates, frequencies of all enriched and of detectable 
MAGE-A3271- and MAGE-A196-specific CD8+ T cells in healthy donors, patients with liver cirrhosis or HCC are depicted (B, C). Dotted 
line indicates limit of detection (10−7 [37];). Statistical analysis was performed using binomial (A–C) test and non-parametric Kruskal-
Wallis test (B, C).
Oncotarget5198www.oncotarget.com
cohort before and in average 3 months after transarterial 
chemoembolization (TACE) (Supplementary Table 1). 
As shown in Figure 4A, 6 out of 13 (46%) HCC patients 
displayed a MAGE-A-specific CD8+ T-cell response prior 
therapy and 6 out of 13 (46%) patients after TACE and 
therefore no increase in the circulating TAA-specific T-cell 
response was observed. In agreement with this finding, we 
also did not observe an increase in the overall frequency 
of MAGE-A-specific CD8+ T cells (Figure 4B) or in the 
percentage of antigen-experienced MAGE-A-specific 
CD8+ T cells (Figure 4C). Thus, these results indicate 
that TACE therapy has no lasting effect on the circulating 
Figure 2: Increased frequencies of circulating antigen-experienced MAGE-A-specific CD8+ T cells in HCC patients. 
Representative flow cytometry plot, percentages (A) and frequencies (B) of circulating antigen-experienced MAGE-A-specific CD8+ T 
cells in HCC patients compared to healthy donors and patients with liver cirrhosis are depicted. Statistical analysis was performed using 
non-parametric Kruskal-Wallis test (*p < 0.005, **p < 0.001).
Figure 3: Frequencies of circulating antigen-experienced virus-specific CD8+ T cells are comparable in healthy donors 
and HCC patients. Representative flow cytometry plots, frequencies (A) and percentages of circulating antigen-experienced (B) MAGE-
A-specific and virus-specific CD8+ T cells are depicted. Statistical analysis was performed using non-parametric Kruskal-Wallis test 
(*p < 0.005, **p < 0.001).
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TAA-specific CD8+ T-cell profile within our available 
sample collection.
Circulating TAA-specific CD8+ T-cell responses 
are linked to the presence of TAA in tumor tissue
One obvious explanation for the limited TAA-
specific CD8+ T-cell response could be restricted 
antigen expression. To address this possibility, we 
analyzed available HCC tissue from 12 patients 
(Supplementary Table 1) for MAGE-A antigen expression 
by immunohistochemistry and included testis tissue as 
positive control (Supplementary Figure 2). As shown 
in Figure 5A and Supplementary Figure 3A, and in 
agreement with the literature [14], we found MAGE-A 
expression in 5 out of 12 tested samples (42%). Thereby, 
the level of antigen expression was quite heterogeneous 
as shown in the representative stainings in Figure 5A. 
Next, we compared the presence of antigen in tumor tissue 
with the detection of MAGE-A-specific CD8+ T-cell 
responses (Figure 5B and 5C). Importantly, in all HCC 
patients with detectable antigen, we also found MAGE-A-
specific CD8+ T-cell responses. These MAGE-A-specific 
CD8+ T-cell populations were heterogeneously composed 
of phenotypically naïve and antigen-experienced cells 
(Supplementary Figure 3B). In contrast, none of the 7 
patients without detectable antigen displayed a MAGE-A-
specific CD8+ T-cell response. Thus, these results strongly 
suggest that presence of antigen is linked to the detection 
of circulating TAA-specific CD8+ T cells in HCC patients; 
however, still a decent proportion of these cells exhibit a 
naïve phenotype.
Circulating TAA-specific CD8+ T cells in HCC 
patients do not display an exhausted phenotype
TAA-specific CD8+ T cells detectable in HCC 
patients have been reported to be dysfunctional and probably 
exhausted [6, 14]. To address this issue in more depth, we 
performed a comprehensive phenotypical analysis of the 
enriched antigen-experienced MAGE-A196- and MAGE-
A3271-specific CD8+ T cells obtained from blood of 
patients with HCC compared to liver cirrhosis, respectively. 
Surprisingly, as shown in Figure 6A, the majority of 
circulating antigen-experienced MAGE-A-specific CD8+ T 
cells did not express PD1 that is upregulated on exhausted 
cells. In line with this, we also did not observe a significant 
expression of the ectonucleotidase CD39 (Figure 6B) that 
has previously been reported to mark terminally exhausted 
CD8+ T-cell populations [26]. In addition, we also analyzed 
expression of the transcription factors Eomes and Tbet 
since high expression levels of Eomes accompanied by 
low Tbet expression has been linked to T-cell exhaustion 
[27]. However, MAGE-A-specific CD8+ T cells did not 
show strong Eomes expression in most patients (Figure 6C) 
contrasting an exhausted state of differentiation. In addition, 
the transcription factor Tbet was highly expressed in 
circulating MAGE-A-specific CD8+ T cells from patients 
suffering from liver cirrhosis and HCC (Figure 6D) rather 
pointing towards an effector/memory phenotype. In 
agreement with this finding, we found a high expression 
of the transcription factor TCF1 (Figure 6E) and the 
interleukin-7 receptor α-chain (CD127; Figure 6F) that 
are both central in the maintenance of memory T cells and 
that are typically downregulated in terminally exhausted 
CD8+ T cells. Taken together, these results demonstrate that 
circulating antigen-experienced MAGE-A-specific CD8+ T 
cells do not display the expected highly exhausted but rather 
an effector/memory phenotype. Noteworthy, we also did not 
find significant differences in the phenotype of MAGE-A-
specific CD8+ T cells present in patients with liver cirrhosis 
versus HCC.
To address the question whether this surprising 
absence of an exhausted phenotype of circulating TAA-
specific CD8+ T cells simply results from the lack 
of antigen expression and thus absence of potentially 
continuous antigen recognition, we phenotypically 
analyzed MAGE-A-specific CD8+ T cells in HCC 
patients with confirmed antigen expression in tumor 
tissue. We did not find any phenotypical differences of 
Figure 4: TACE does not enhance circulating TAA-specific CD8+ T-cell responses in HCC patients. Detection rates 
of MAGE-A-specific CD8+ T-cell responses (black versus grey: not detectable) before and after TACE are depicted in pie charts (A). 
Frequencies (B) and percentages of antigen-experienced (C) MAGE-A-specific CD8+ T-cell responses before and after TACE in HCC 
patients (HCC#4, 9, 19, 21–23, 27, 29, 32, 55–58) are displayed. Bar charts show median values with interquartile range. Statistical analysis 
was performed using binomial test (A) and non-parametric paired Wilcoxon test (B, C).
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antigen-experienced MAGE-A-specific CD8+ T cells 
present in these HCC patients with verified antigen 
expression compared to the overall tested cohort of 
HCC patients in which we could not confirm respective 
TAA expression due to the lack of appropriate tumor 
samples (Supplementary Figure 3C–3G). This suggests 
that the absence of circulating TAA-specific CD8+ 
T-cell exhaustion cannot be explained by lack of antigen 
expression. Interestingly, however, immunohistochemical 
analyses of liver tissue from HCC patients revealed a 
Figure 5: TAA-specific CD8+ T-cell responses in HCC patients are associated with the presence of TAA in tumor tissue. 
MAGE-A expression is heterogeneous in HCC tissue. Immunohistochemical analysis (MAGE-A: brown) of paraffin-embedded HCC 
tissue including negative controls (without primary antibody) and pie charts depicting the detection rate of MAGE-A (black: detectable 
versus grey: not detectable) are displayed (A). MAGE-A detection in HCC tissue and detection of circulating MAGE-A-specific CD8+ 
T cells correlates. Representative histological analyses (MAGE-A: brown), corresponding flow cytometry plots of circulating MAGE-A-
specific CD8+ T-cell responses (B), tabular and pie chart analysis (C) are depicted.
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rather low infiltration of the tumor by CD8+ T cells 
(Supplementary Figure 4). Thus, TAA-specific CD8+ 
T cells may not exhaust since antigen recognition is 
restricted by exclusion from the sites within the tissue 
where antigen is expressed.
DISCUSSION
Our comprehensive study using a highly sensitive 
pMHCI-tetramer-based enrichment strategy gives 
important novel insights into circulating TAA-specific 
CD8+ T-cell responses in therapy-naïve HCC patients. 
First, in agreement with several previous reports, our 
results show that they are present only in a very low 
frequency. Indeed, we could not detect circulating TAA-
specific CD8+ T-cell responses directly ex vivo but 
only after enrichment in the analyzed HLA-A*0201 or 
HLA-A*0301 positive patients. By this approach, NY-
ESO-1 and Glypican-3-specific CD8+ T cells were still 
only detectable in less than 15% of patients, whereas 
MAGE-A-specific CD8+ T cells were present in about 
half of the patients. This is still a very low detection rate 
considering the high sensitivity of the enrichment strategy 
that allows e. g. the detection of HCV-specific CD8+ T 
cells in all patients tested [24]. The low detection rate 
despite pMHCI-tetramer enrichment indicates a very 
low frequency of circulating TAA-specific CD8+ T cells 
and may also explain their limited clinical efficacy in 
many tumor entities. Noteworthy, different hierarchies 
and immunodominances of TAA-specific CD8+ T-cell 
responses within different cohorts of HCC patients have 
been previously reported [6, 7, 14]. However, most of 
Figure 6: Circulating TAA-specific CD8+ T cells are not exhausted in HCC patients. Phenotypes of circulating MAGE-
A-specific CD8+ T cells are similar in patients with liver cirrhosis and HCC patients with no signs of exhaustion. Representative flow 
cytometry plots and bar charts depicting expression of PD1 (A), CD39 (B), Eomes (C), Tbet (D), TCF1 (E) and CD127 (F) on antigen-
experienced MAGE-A-specific CD8+ T cells are displayed. Statistical analysis was performed using unpaired t-test.
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those were depending on in vitro expansion protocols prior 
ELISPOT assays that may not allow the full recapitulation 
of the TAA-specific CD8+ T-cell frequency ex vivo. These 
studies have also indicated a significant heterogeneity 
and no consistent hierarchy between different TAA-
specific CD8+ T-cell responses within single cohorts of 
HCC patients [6, 7, 14]. Noteworthy, however, also by 
these approaches, the strongest responses were found 
to be directed against MAGE-A [6]. The significantly 
higher expression levels of MAGE-A versus NY-ESO-1 
[8, 28] that have been reported not only in HCC but also 
in different tumors further support its better immunogenic 
potential and also fits to our finding with dominant 
MAGE-A-specific CD8+ T-cell responses.
Interestingly, however, the frequency of circulating 
MAGE-A-specific CD8+ T-cell responses was not higher 
in the analyzed HCC patients compared to patients 
with liver cirrhosis and healthy donors and was thus 
in the range of the naïve precursor frequency. This is a 
somewhat surprising finding since it suggests a limited 
TAA-specific CD8+ T-cell response induction and 
expansion in therapy-naïve HCC. This finding cannot 
be completely explained by absence of priming since a 
large fraction of TAA-specific CD8+ T cells displayed an 
antigen-experienced phenotype. However, within the same 
TAA-specific CD8+ T-cell responses present in HCC, T 
cells with a naïve phenotype could also be detected. This 
indicates an at least partially inefficient TAA-specific 
CD8+ T-cell priming and activation that may result 
in limited expansion and thus low frequencies hardly 
differing from naïve precursor frequencies. In contrast, 
virus-specific CD8+ T-cell responses present in the 
same patients showed a completely antigen-experienced 
phenotype, arguing against an actively ongoing general 
cancer-associated mechanism of improper T-cell priming 
in HCC. Combined, these results indicate an inefficient 
recruitment of circulating TAA-specific CD8+ T cells to 
the effector pool, the mechanisms of which are not well 
understood. One simple explanation could be the absence 
of respective antigens in the tumor tissue. However, we 
found antigen corresponding to TAA-specific CD8+ T 
cells expressed in 5 out of 12 analyzed tumor samples. 
In addition, the presence of antigen was associated with 
the detection of antigen-experienced TAA-specific CD8+ 
T cells, but a considerable proportion of cells with a 
naïve phenotype was still detectable. Thus, these results 
indicate that the inefficient activation and expansion of 
TAA-specific CD8+ T-cell responses cannot solely be 
explained by lack of antigen. It should be however noted 
that we cannot exclude the possibility that we may have a 
selection of escape mutations in the targeted TAA epitope 
in the analyzed patients.
It has been postulated that different HCC therapies 
such as radiofrequency ablation or TACE lead to an 
activation and enhancement of TAA-specific CD8+ T-cell 
responses probably reflecting activation by antigen release 
and/or induction of danger signals by tumor necrosis and 
or apoptosis [6, 23, 29–31]. However, in our study, by 
using a pMHCI-tetramer-based enrichment strategy, we 
did not find an increase in the detection rate, frequency 
or percentage of circulating antigen-experienced TAA-
specific CD8+ T cells after TACE, further questioning the 
exclusive role of antigen in driving TAA-specific CD8+ 
T-cell activation. Importantly, we want to emphasize that 
blood sampling was conducted in average 28 days after 
TACE. Thus, the previously described transient increase 
in the frequencies of TAA-specific CD8+ T cells after 
therapy-induced local tumor destruction [7, 23, 30] was 
probably missed in our HLA-A2- and HLA-A3 restricted 
cohort. Of note, also a transient induction of TAA-specific 
T-cell responses after the local ablative TACE treatment 
could still have possible relevance for the course of 
combination therapies.
Probably the most important and surprising finding 
of our study is that detectable and circulating antigen-
experienced TAA-specific CD8+ T cells in therapy-naïve 
HCC patients do not display a phenotype indicative of 
T-cell exhaustion. Indeed, the TAA-specific CD8+ T 
cells do not show high expression of PD1 or Eomes, both 
typical markers of T-cell exhaustion but rather strongly 
expressed TCF1 and CD127, markers characteristic for 
memory cells harboring a good proliferative capacity [32]. 
Of note, a moderate expression of inhibitory receptors 
on TAA-specific CD8+ T cells has also been previously 
reported in different cohorts of HCC patients with different 
underlying etiologies [14, 17, 18, 20]. Interestingly, 
these receptors were higher expressed on TAA-specific 
CD8+ T cells isolated from HCC tissue compared with 
T cells from tumor-free liver tissue or blood, although 
the tolerogenic liver environment itself has been shown 
to induce an upregulation of inhibitory receptors on T 
cells [18, 20]. Further analyses are therefore required to 
dissect the mechanisms underlying the expression of co-
inhibitory receptors on intrahepatic TAA-specific CD8+ 
T cells. There are several possible explanations for our 
finding that at least peripheral TAA-specific CD8+ T cells 
do not show an exhausted phenotype due to ineffective 
activation. For example, failure of TAA presentation by 
antigen presenting cells as a consequence of decreased 
expression of HLA class I molecules or ineffective tumor 
antigen processing. This would also explain the overall 
low T-cell infiltration of the tumors in our study. In this 
context it is interesting to note that a strong MAGE-A-
specific CD8+ T-cell response in concert with a significant 
T-cell infiltration has been reported in one patient where 
the tumor mass expanded out of the liver and infiltrated 
the peritoneum and diaphragmatic muscle [9]. Thus, these 
results link high antigen load and maybe even priming 
outside the liver with strong T-cell infiltration and TAA-
specific CD8+ T-cell response. However, as such a 
scenario is rarely seen it further supports the hypothesis 
that absence of efficient priming is one hallmark of TAA-
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specific CD8+ T-cell failure in therapy-naïve HCC. It is 
also possible that other immune cell populations such as 
increases in regulatory T cells, myeloid-derived suppressor 
cells [17, 19, 21, 22] or tumor-associated macrophages 
[21] or lack of CD4+ T-cell help [18, 19] contribute to the 
observed TAA-specific CD8+ T-cell alterations.
The absence of TAA-specific CD8+ T-cell 
exhaustion in HCC is also surprising in light of a recent 
report showing that the PD1 inhibitor nivolumab leads 
to durable objective responses in patients with advanced 
HCC [5]. Also, recent gene expression analyses of HCC 
samples and deep single-cell RNA sequencing on T cells 
isolated from peripheral blood and HCCs revealed the 
existence of specific subsets of exhausted CD8+ T cells 
[33]. Indeed, 25% of HCCs were reported to have markers 
of an inflammatory response with high expression of 
PD1 that was also found to be highly expressed on HCC 
infiltrating T cells by single cell sequencing. While these 
results clearly show the existence of T-cell exhaustion in 
a subset of HCCs, they have not addressed the antigen-
specificity of these responses. Based on our finding that 
circulating TAA-specific CD8+ T-cell responses are not 
exhausted, it is tempting to speculate that these T-cell 
responses are largely targeting neoantigens. Noteworthy, 
however, no correlation between the mutation load or the 
presence of neoantigens and the presence of inflammatory 
responses was observed in one study [34]. A similar lack 
of association has also been reported for other tumor 
entities with a similar rather modest mutational burden, 
such as prostate or ovarian cancer where the quality or 
clonality of neoantigens rather than the quantity has been 
suggested to shape the immune response [35, 36]. Clearly, 
further research is needed to define the targets of T-cell 
responses in HCC. However, our finding of not exhausted 
circulating TAA-specific CD8+ T-cell responses in a large 
cohort of HCC patients points towards the targeting of 
other antigens, such as neoantigens, that may drive T-cell 
exhaustion in natural HCC and may thus represent an 
optimal target of checkpoint inhibitor therapies.
Our study has some limitations. First, due to 
availability and technical feasibility, we could only apply 
a small selection of pMHCI-tetramers. Still, these pMHCI-
tetramers detect TAA-specific CD8+ T cells that were 
shown to be immunodominant and to target antigens that 
were expressed in most tumors. Second, our study was 
limited to samples from the peripheral blood and not from 
tumor tissue since we did not have access to appropriate 
tissue samples. However, the peripheral blood represents 
the best accessible site for diagnostic measures and 
therapeutic interventions.
Taken together, the results of our comprehensive 
study based on a highly sensitive enrichment strategy 
gives novel important insights into HCC immunity by 
showing that circulating TAA-specific CD8+ T-cell 
responses are only present at very low frequencies, that 
they show a heterogeneous phenotype ranging from a 
naïve to an antigen-experienced phenotype indicating 
improper activation or priming, that they are not stably 
enhanced by TACE and probably most importantly, that 
they are not showing a phenotype indicative of T-cell 
exhaustion. These results show severe limitations of TAA-
specific CD8+ T-cell responses present in therapy-naïve 
HCC that despite the presence of cognate antigen seem 
not be properly established. These results have important 
implications for immunotherapy as they highlight the 
challenge to induce TAA-specific CD8+ T-cell responses 
by vaccination or checkpoint inhibitors. They also suggest 
that other antigens, such as neoantigens, that have not 
been well-defined in HCC, may be primary targets of 
T-cell responses in therapy-naïve HCC. Clearly, important 
obstacles lie ahead that need to be addressed to fully 
uncover the potential of T-cell-targeted immunotherapy 
for the treatment of HCC.
MATERIALS AND METHODS
Study cohort
54 HCC patients (Supplementary Table 1), 28 
healthy donors (Supplementary Table 2) and 29 patients 
with liver cirrhosis (Supplementary Table 3) were recruited 
at the Department of Medicine II of the University 
Hospital Freiburg, Germany. Written informed consent 
was obtained in all cases and the study was conducted 
according to the Declaration of Helsinki (1975), federal 
guidelines and local ethics committee regulations (Albert-
Ludwigs-University, Freiburg, Germany, approvals 474/14 
and 152/17). All analyzed HCC patients have not received 
immunotherapy and were mainly treated with local 
ablative TACE therapy (Supplementary Table 1).
PBMC isolation
Peripheral blood mononuclear cells (PBMCs) were 
isolated from EDTA anti-coagulated blood by density-
gradient centrifugation. For all analyses, frozen PBMCs 
were thawed in complete medium (RPMI 1640 with 10% 
fetal bovine serum, 1% penicillin/streptomycin and 1.5% 
1M HEPES (all Thermo Fisher, Germany)) and incubated 
with 50 U/mL benzonase (Sigma, Germany) before further 
procedure.
pMHCI-tetramers
pMHCI-tetramers consist of biotinylated pMHCI-
monomers (provided by David A. Price) complexed 
by phycoerythrin (PE)- or allophycocyanin (APC)-
labelled streptavidin at a molar ratio of 5:1. HLA-A*02-
tetramers carrying previously described TAA epitopes 
(NY-ESO-1157-165: SLLMWITQA [12]; Glypican-3521-530: 
FLAELAYDL [18]; AFP47-55: ATIFFAQFV [6] and 
MAGE-A3271-279: FLWGPRALV [6]) or viral epitopes 
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(Cytomegalovirus (CMV) pp65495-503: NLVPMVATV, 
Epstein-Barr virus (EBV) BMFL1280-288: GLCTLVAML 
and Influenza A virus M158-66: GILGFVFTL); and HLA-
A*03-tetramers carrying TAA epitopes (MAGE-A196-104: 
SLFRAVITK [6] and Glypican-3519-528: QLRFLAELAY 
[6]) were used.
pMHCI-tetramer-based enrichment
pMHCI-tetramer-based enrichment and subsequent 
calculation of TAA-specific CD8+ T-cell frequencies 
were performed as previously described by Alanio et al. 
[37]. Briefly, 50 Mio PBMCs were incubated for 30 min 
with PE- or APC-labeled pMHCI-tetramers. Anti-PE/
APC MACS beads (Miltenyi Biotec, Germany) were used 
according to the manufacturer’s protocol.
Frequency Tetramer CD Tcells
Tetramer CD T ells Enr
 of  
 c
+ +
=
+ +
8
8# ( iched
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)
  n  of  8 +
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= #CD8+T cells Pre Enrichmen( t x #PBMC count
# single cells Pre Enrichment
)
( )
pMHCI-tetramers were titrated for optimal amount. 
The following tetramer amounts were used: 20 nM 
NY-ESO-1157-165; 3 nM Glypican-3521-53, 3 nM, AFP47-
55, 3 nM, MAGE-A3271-279, 1 nM MAGE-A196-104, 3 nM 
Glypican-3519-528, 1 nM, CMV pp65495-503, 1 nM, EBV 
BMFL1280-288 and 1 nM, Influenza A virus M158-66.
Flow cytometry
For flow cytometry the following antibodies were 
used: anti-Eomes (WD1928), anti-Tbet (4B10), anti-
CD14 (61D3), anti-CD19 (HIB19), anti-CCR7 (G043H7), 
anti-CD127 (A019D5), anti-CD45RA (HI100), anti-PD1 
(EH12.2H7), anti-CD8 (HIT8a), Donkey anti-Rabbit IgG 
(Poly4064) (all BioLegend, San Diego, CA, USA); anti-
TCF1 (C63D9) (Cell Signaling, Germany); anti-CD39 
(TU66), and anti-CD8 (RPA-T8) (both BD Biosciences, 
Germany). Fixable Viability Dyes (eFluor780, eBioscience, 
Germany) was used for live/dead discrimination. FoxP3/
Transcription Factor Staining Buffer Set (eBioscience, 
Germany) was applied according to the manufacturer’s 
instructions for intranuclear staining. Cells were fixed 
with paraformaldehyde (2% PFA) and analyzed using a 
LSRFortessa (BD Biosciences, Germany). Flow cytometry 
data were analyzed using FlowJo software V10 (Treestar, 
USA). Gating strategy is shown in Supplementary Figure 
1. After exclusion of CD45RA+CCR7+ naïve T cells, 
marker analysis was restricted to patients showing at least 
five antigen-experienced MAGE-A-specific CD8+ T cells. 
Dump channel includes dead cells, CD14+ and CD19+ cells.
HLA typing
HLA-typing was performed by next generation 
sequencing using commercially available primers (GenDx, 
Utrecht, The Netherlands) and run on a MiSeq system 
(Illumina). Data were analyzed using the NGSengine® 
Software (GenDx).
Immunohistochemistry
For MAGE-A1 and MAGE-A3 antigen detection 
in tumor tissue, paraffin-embedded slices from 12 HCC 
patients were analyzed. Sections were de-waxed in 
xylene/ethanol before target retrievel in citrate pH6 buffer 
(DakoCytomation Target Retrieval Solution Citrate pH6 
(10×) (S2369) or DAKO Target Retrieval Solution, pH9 
(10×) (S2367)) for 20 min. After peroxidase inactivation 
via Peroxidase Blocking (K5007: HRP EnVision FLEX 
Peroxidase Blocking Reagent (DAKO SM801), sections 
were stained with the specific primary anti- CD8 
(C8/144B, 1:60, Dako), MAGE-A1 (MA454, 1:100) or 
MAGE-A3 (polyclonal, 1:100) (Sigma). EnVision FLEX 
mouse Linker (DAKO SM804) was used to enhance 
the MAGE staining. Antibodies were detected using a 
biotinylated anti-mouse IgG followed by an incubation 
with peroxidase-conjugated avidin. Sections were 
counterstained with Mayer´s hematoxylin (Sigma Aldrich, 
Germany).
Statistics
Statistical analysis was performed with GraphPad 
Prism 6 (GraphPad Software, La Jolla, CA, USA).
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